Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICCOV DNA Vaccine Booster Trial
NCT05904054Phase 2Completed
- Sponsor
- Immuno Cure
- Start
- Jun 2023
- Primary completion
- Dec 2023
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of ICCOV in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Immuno Cure. Primary endpoints: Frequencies of cross-reactive receptor binding domain (RBD)-specific IFN-γ producing T cells at Day 28, Frequencies of cross-reactive receptor binding domain (RBD)-specific CD4+ T cells at Day 28 and 1 more. Started Jun 2023; status: completed.
02
Drugs
ICCOV
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05904054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05904054.